Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | STING1 | Q86WV6 | 15/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.78 |
| ▸ | GMNN | O75496 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.78 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15906306 | 1.00 | KMT2A (1.00) | KMT2AMEN1ALDH1A1STING1LMNA | |
| SCHEMBL1106650 | 1.00 | KMT2A (1.00) | KMT2AMEN1ALDH1A1STING1LMNA | |
| SCHEMBL1106664 | 1.00 | KMT2A (1.00) | KMT2AMEN1ALDH1A1STING1LMNA | |
| SCHEMBL29515507 | 1.00 | KMT2A (1.00) | KMT2AMEN1ALDH1A1STING1LMNA | |
| SCHEMBL10098850 | 1.00 | KMT2A (1.00) | KMT2AMEN1ALDH1A1STING1LMNA | |
| SCHEMBL29368433 | 0.96 | KMT2A (0.93) | KMT2AMEN1ALDH1A1STING1LMNA | |
| SCHEMBL29478470 | 0.96 | KMT2A (0.93) | KMT2AMEN1ALDH1A1STING1LMNA | |
| Ammonia Solution, Strong SCHEMBL29465897 | 0.95 | KMT2A (0.91) | KMT2AMEN1ALDH1A1STING1LMNA | |
| SCHEMBL29712629 | 0.94 | KMT2A (0.88) | KMT2AMEN1ALDH1A1STING1LMNA | |
| SCHEMBL5151491 | 0.89 | KMT2A (0.80) | KMT2AMEN1ALDH1A1STING1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185100-B2 | Methods for modulating taste receptors | MARS, INCORPORATED (US) | 2021-11-30 | — | — | US | claimed |
| US-20090197279-A1 | MICROTUBULE SYNTHESIS AS A BIOMARKER | KINEMED, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| EP-1949085-A2 | MICROTUBULE SYNTHESIS AS A BIOMARKER | Kinemed, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | IKARIA, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| WO-2007041611-A2 | MICROTUBULE SYNTHESIS AS A BIOMARKER | KINEMED, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-5625056-A | INHIBITORS OR STIMULANTS FOR KINASES FOR LIGANDS FOR CHROMATOGRAPHY | BIOLOG LIFE SCIENCE INSTITUTE (DE) | 1997-04-29 | — | — | US | disclosed |
| US-5552267-A | PHOSPHODIESTERASE INHIBITORS, GLUCOSE, MAGNESIUM IONS, BUFFERS, MAGNESIUM IONS AS MACROMOLECULES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1996-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | ADORA2A, ADORA2B, ADORA1 | KMT2A 3573/4885MEN1 4450/4885ALDH1A1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.